Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Thyroid Gland Medullary Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Early research (Phase 1)Study completedNCT03780517
What this trial is testing

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Who this might be right for
Advanced Nonhaematologic Malignancies
Boston Pharmaceuticals 117
Testing effectiveness (Phase 2)WithdrawnNCT04106843
What this trial is testing

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Who this might be right for
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+11 more
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT04537715
What this trial is testing

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Who this might be right for
All MalignanciesAdvanced MalignanciesHematologic Malignancy+9 more
Epizyme, Inc. 42
Testing effectiveness (Phase 2)WithdrawnNCT03838692
What this trial is testing

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Antonio Fojo
Large-scale testing (Phase 3)Study completedNCT00410761
What this trial is testing

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Genzyme, a Sanofi Company 331
Not applicableStudy completedNCT01945762
What this trial is testing

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

Who this might be right for
Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
Genzyme, a Sanofi Company 31
Testing effectiveness (Phase 2)Study completedNCT00095836
What this trial is testing

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Who this might be right for
Head and Neck Cancer
Massachusetts General Hospital 27
Testing effectiveness (Phase 2)Study completedNCT01874873
What this trial is testing

A Phase II Study of Anlotinib in MTC Patients

Who this might be right for
Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 58
Early research (Phase 1)Study completedNCT00005647
What this trial is testing

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Who this might be right for
Head and Neck Cancer
Case Comprehensive Cancer Center 12
Early research (Phase 1)Study completedNCT00098943
What this trial is testing

NGR-TNF in Treating Patients With Advanced Solid Tumors

Who this might be right for
Colorectal CancerHead and Neck CancerKidney Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC 70
Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07816770
What this trial is testing

MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas

Who this might be right for
Metastatic Non-Clear Cell Renal Cell CarcinomaMetastatic Renal Medullary Carcinomas
Fudan University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03899792
What this trial is testing

Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Who this might be right for
Medullary Thyroid CancerInfantile MyofibromatosisInfantile Fibrosarcoma+2 more
Eli Lilly and Company 36
Testing effectiveness (Phase 2)Study completedNCT01164176
What this trial is testing

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Head and Neck Cancer
Yonsei University 40
Early research (Phase 1)Not Yet RecruitingNCT07252661
What this trial is testing

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more
AccSalus Biosciences, Inc. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04211337
What this trial is testing

Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer
Loxo Oncology, Inc. 291
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Next Page